Trieu Vuong's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jul 10, 2025
- Accession no.
- 0001641172-25-018620
- Filed
- Jul 10, 2025, 5:15 PM ET
- Trade date
- Jul 8-10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $993.69. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trieu VuongCIK 0001587074 | Director, Officer (CHAIRMAN AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2025 | Common Stock | PPurchaseAcquired | +104,000 | $0.005 | +$520 | 93,293,560 | Direct | |
| Jul 9, 2025 | Common Stock | PPurchaseAcquired | +1 | $0.005 | +$0.01 | 93,293,561 | Direct | |
| Jul 8, 2025 | Common Stock | PPurchaseAcquired | +94,736 | $0.005 | +$473.68 | 93,388,297 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.